Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43801   clinical trials with a EudraCT protocol, of which   7258   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools

    < Back to search results

    Print Download

    EudraCT Number:2017-003539-12
    Sponsor's Protocol Code Number:BIVV009-04
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2017-11-07
    Trial results View results
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2017-003539-12
    A.3Full title of the trial
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A study to determine the safety and effectiveness of study drug BIVV009 in patients with Primary Agglutinin Disease without recent history of blood transfusions
    Un estudio para determinar la eficacia y efectividad del farmaco en estudio BIVV009 en pacientes con enfermedad por crioaglutininas primaria que no han recibido transfusiones sanguíneas recientemente
    A.3.2Name or abbreviated title of the trial where available
    A.4.1Sponsor's protocol code numberBIVV009-04
    A.5.4Other Identifiers
    Name:IND #Number:128,190
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorBioverativ USA Inc.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportBioverativ USA Inc.
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationBioverativ USA Inc.
    B.5.2Functional name of contact pointClinical Trial Dept
    B.5.3 Address:
    B.5.3.1Street Address225 Second Avenue
    B.5.3.2Town/ cityWaltham, MA
    B.5.3.3Post code02451
    B.5.3.4CountryUnited States
    B.5.4Telephone number+3491145911000
    B.5.5Fax number+349143427700
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEMA/OD/177/15
    D.3 Description of the IMP
    D.3.1Product nameBIVV009
    D.3.2Product code BIVV009
    D.3.4Pharmaceutical form Solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNBIVV009
    D.3.9.2Current sponsor codeBIVV009
    D.3.9.3Other descriptive nameCOMPLEMENT C1 ESTERASE INHIBITOR
    D.3.9.4EV Substance CodeSUB22696
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number18
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D. cell therapy medicinal product No
    D. therapy medical product No
    D. Engineered Product No
    D. ATIMP (i.e. one involving a medical device) No
    D. on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboSolution for infusion
    D.8.4Route of administration of the placeboIntravenous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Primary Cold Agglutinin Disease
    Enfermedad por crioaglutininas primaria
    E.1.1.1Medical condition in easily understood language
    Autoimmune Disease against red blood cells (Haemolytic Anaemia)
    Enfermedad autoinmune que ataca los glóbulos rojos (anemia
    E.1.1.2Therapeutic area Diseases [C] - Immune System Diseases [C20]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10073785
    E.1.2Term Autoimmune haemolytic anaemia
    E.1.2System Organ Class 10005329 - Blood and lymphatic system disorders
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective of Part A is to determine whether BIVV009 administration results in a ≥ 1.5 g/dL increase in hemoglobin (Hgb) level and avoidance of transfusion in patients with primary CAgD without a recent history of blood transfusion.

    The primary objective of Part B is to evaluate the long-term safety and tolerability of BIVV009 in patients with primary CAgD.
    El objetivo principal de la Parte A es determinar si la administración del BIVV009 produce un aumento ≥ 1,5 g/dl en el valor de hemoglobina (Hb) y evita la necesidad de transfusiones en pacientes con enfermedad por crioaglutininas primaria que no han recibido transfusiones sanguíneas recientemente.
    El objetivo principal de la Parte B es evaluar la seguridad a largo plazo y la tolerabilidad del BIVV009 en pacientes con enfermedad por crioaglutininas primaria.
    E.2.2Secondary objectives of the trial
    The secondary efficacy objectives of Part A are:
    To assess the effect of BIVV009 on clinical events and laboratory parameters related to hemolysis and anemia in patients with primary CAgD
    To assess the effect of BIVV009 on specific complications of CAgD
    To assess the effect of BIVV009 on quality of life (QOL) in patients with primary CAgD.

    The secondary objective of Part B is to investigate the durability of response during long-term treatment with BIVV009 in patients with primary CAgD.
    Los objetivos secundarios de eficacia de la Parte A son:
    Evaluar el efecto del BIVV009 en los episodios clínicos y los parámetros de laboratorio de hemólisis y anemia en pacientes con enfermedad por crioaglutininas primaria.
    Evaluar el efecto del BIVV009 sobre las complicaciones características de la enfermedad por crioaglutininas.
    Evaluar el efecto del BIVV009 sobre la calidad de vida (CdV) en pacientes con enfermedad por crioaglutininas primaria.

    El objetivo secundario de la Parte B es estudiar la duración de la respuesta en el transcurso del tratamiento a largo plazo con BIVV009 en pacientes con enfermedad por crioaglutininas primaria.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    All patients must meet all the following inclusion criteria to be enrolled:
    1.Adult male and female patients ≥ 18 years of age at Screening
    2.Body weight of ≥ 39 kg at Screening
    3.Confirmed diagnosis of primary CAgD based on the following criteria:
    a.Chronic hemolysis
    b.Polyspecific direct antiglobulin test (DAT) positive
    c.Monospecific DAT strongly positive for C3d
    d.Cold agglutinin titer ≥ 64 at 4 degrees Celsius
    e.IgG DAT ≤ 1+, and
    f.No overt malignant disease
    4.Hemoglobin level ≤ 10.0 g/dL
    5.Bilirubin level above the normal reference range
    6.Ferritin levels within the normal reference ranges unless outside normal range and deemed not clinically significant by the Investigator (or designee)
    7.Presence of one or more of the following CAgD-related signs or symptoms within 3 months of Screening:
    a.Symptomatic anemia defined as:
    iii.Shortness of breath
    iv.Palpitations, fast heart beat
    v.Light headedness and/or
    vi.Chest pain
    c.Raynaud’s syndrome
    e.Disabling circulatory symptoms, and/or
    f.Major adverse vascular event (including thrombosis)
    8.Bone marrow biopsy within 6 months of Screening with no overt evidence of lymphoproliferative disease or other hematological malignancy. An additional bone marrow biopsy will be required if the prior bone marrow is deemed unsuitable for analysis by the Sponsor.
    9.Vaccinations against encapsulated bacterial pathogens (Neisseria meningitis, Meningitis B, Haemophilus influenzae, and Streptococcus pneumoniae) within 5 years of enrollment or as specified in Appendix B
    10.Adequate IV access
    11.If female, must be post-menopausal, surgically sterile, or be established on (≥ 3 months prior to Screening) and agree to continue to use the same highly effective methods of birth control throughout the study and for 6 weeks following administration of the last dose of study drug
    12.Males must be surgically sterile for at least 90 days or when sexually-active with female partners of child-bearing potential will agree to use highly effective contraception from Day 0 until 6 weeks following administration of the last dose of study drug
    13.Able to comprehend and give informed consent
    14.Able to comply with the requirements of the study and to complete the full sequence of protocol-related procedures.
    Para ser incluidos, todos los pacientes deberán cumplir la totalidad de los criterios de inclusión que se presentan a continuación:
    1.Hombres y mujeres adultos, de ≥ 18 años de edad en el momento de la selección.
    2.Peso corporal ≥ 39 kg en el momento de la selección.
    3.Diagnóstico confirmado de enfermedad por crioaglutininas primaria, según los siguientes criterios:
    a.Hemólisis crónica,
    b.Prueba de antiglobulina directa (PAD) poliespecífica positiva,
    c.PAD monoespecífica marcadamente positiva para C3d,
    d.Título de crioaglutininas ≥ 64 a 4○C,
    e.PAD IgG ≤ 1+, y
    f.Ausencia de neoplasia maligna manifiesta.
    4.Valor de hemoglobina ≤ 10.0 g/dl.
    5.Valor de bilirrubina por encima del valor normal de referencia.
    6.Valor de ferritina dentro del intervalo de valores normales de referencia, salvo que se encuentre fuera del intervalo de normalidad pero que el investigador (o la persona que haya designado) considere que no tiene importancia clínica.
    7. Presencia de uno o más de los siguientes signos o síntomas de la enfermedad por crioaglutininas en los 3 meses previos a la selección:
    a. Anemia sintomática, definida como:
    i. Cansancio
    ii. Debilidad
    iii. Dificultad para respirar
    iv. Palpitaciones, frecuencia cardiaca acelerada
    v. Sensación de mareo y/o
    vi. Dolor torácico
    b. Acrocianosis
    c. Síndrome de Raynaud
    d. Hemoglobinuria
    e. Síntomas circulatorios incapacitantes y/o
    f. Complicaciones vasculares graves (incluida la trombosis)
    8. Biopsia de médula ósea en los 6 meses previos a la selección, sin evidencia manifiesta de enfermedad linfoproliferativa u otra neoplasia maligna hematológica. Será necesaria otra biopsia de médula ósea si el promotor considera que la biopsia anterior es inadecuada para su análisis.
    9. Vacunación contra bacterias patógenas encapsuladas (Neisseria meningitidis, Meningitis B, Haemophilus influenzae y Streptococcus pneumoniae) en los 5 años previos a la inclusión o según lo especificado en el Apéndice B.
    10. Acceso i.v. adecuado.
    11. Las mujeres deberán encontrarse en periodo postmenopáusico, ser quirúrgicamente estériles o estar utilizando de manera estable (≥ 3 meses antes de la selección) un método anticonceptivo muy eficaz y estar de acuerdo en seguir utilizándolo en el transcurso del estudio y durante las 6 semanas posteriores a la administración de la última dosis del medicamento del estudio.
    12. Los hombres deberán haberse sometido a esterilización quirúrgica 90 días antes como mínimo o, en caso de tener relaciones sexuales con mujeres con capacidad de quedarse embarazadas, deberán aceptar utilizar un método anticonceptivo muy eficaz desde el día 0 hasta 6 semanas después de la administración de la última dosis del medicamento del estudio.
    13.Capacidad para comprender y otorgar un consentimiento informado.
    14.Capacidad para cumplir los requisitos del estudio y realizar la secuencia completa de los procedimientos establecidos en el protocolo.
    E.4Principal exclusion criteria
    Patients who meet any of the following criteria will be excluded from the study:
    1.Cold agglutinin syndrome secondary to infection, rheumatologic disease, or active hematologic malignancy
    2.History of 1 or more blood transfusions within 6 months of enrollment
    3.Clinically relevant infection of any kind within the month preceding enrollment (eg, active hepatitis C, pneumonia)
    4.Clinical diagnosis of SLE; or other autoimmune disorders with anti-nuclear antibodies at Screening
    5.Positive hepatitis panel (including hepatitis B surface antigen and/or hepatitis C virus antibody) prior to or at Screening
    6.Positive human immunodeficiency virus (HIV) antibody at Screening
    7.Treatment with rituximab monotherapy within 3 months or rituximab combination therapies (eg, with bendamustine, fludarabine, ibrutinib, or cytotoxic drugs) within 6 months prior to enrollment
    8.Concurrent treatment with corticosteroids other than a stable daily dose equivalent to ≤ 10 mg/day prednisone for previous 3 months
    9.Erythropoietin deficiency. Concurrent treatment with erythropoietin is permitted if the patient has been on a stable dose for the previous 3 months
    10.Concurrent usage of iron supplementation unless the patient has been on a stable dose for at least 4 weeks
    11.Clinically significant medical history or ongoing chronic illness that would jeopardize the safety of the patient or compromise the quality of the data derived from his/her participation in this study (as determined by the Investigator [or designee]) at Screening
    12.Concurrent treatment with other experimental drugs or participation in another clinical trial with any investigational drug within 30 days or 5 half lives, whichever is greater, prior to treatment start
    13.Females who are pregnant, lactating, or, if having reproductive potential, are considered potentially unreliable with respect to contraceptive practice.
    Los pacientes que presenten cualquiera de los siguientes criterios serán excluidos del estudio:
    1.Síndrome por crioaglutininas secundario a una infección, enfermedad reumatológica o neoplasia maligna hematológica activa.
    2.Haber recibido 1 o más transfusiones sanguíneas en los 6 meses previos a la inclusión.
    3.Infección clínicamente importante, de cualquier tipo, durante el mes anterior a la inclusión (p. ej., hepatitis C activa, neumonía).
    4.Diagnóstico clínico de lupus eritematoso sistémico (LES); u otros trastornos autoinmunitarios que presenten anticuerpos antinucleares en el momento de la selección.
    5.Resultado positivo de pruebas analíticas de hepatitis (incluidos el antígeno de superficie del virus de la hepatitis B y/o anticuerpos contra el virus de la hepatitis C) antes o en el momento de la selección.
    6.Presencia de anticuerpos contra el virus de la inmunodeficiencia humana (VIH) en el momento de la selección.
    7.Tratamiento con rituximab en monoterapia en los 3 meses previos a la inclusión o con rituximab en politerapia (p. ej., con bendamustina,fludarabina, ibrutinib o medicamentos citotóxicos) en los 6 meses previos a la inclusión.
    8.Tratamiento concomitante con corticoesteroides, distinto a una dosis estable diaria equivalente a ≤ 10 mg/día de prednisona durante los 3 meses anteriores.
    9.Deficiencia de eritropoyetina. Se permite el tratamiento concomitante con eritropoyetina si el paciente ha estado recibiendo una dosis estable durante los 3 meses anteriores.
    10.Uso concomitante de suplementos de hierro, a menos que el paciente haya estado recibiendo una dosis estable durante 4 semanas como mínimo.
    11.Antecedentes médicos clínicamente importantes o enfermedad crónica en curso que podrían amenazar la seguridad del paciente o comprometer la calidad de los datos derivados de su participación en este estudio (según lo determine el investigador [o la persona que haya designado]), en el momento de la selección.
    12. Tratamiento concomitante con otros medicamentos experimentales o participación en otro ensayo clínico con cualquier medicamento en investigación en los 30 días o un periodo equivalente a 5 semividas, el periodo que sea mayor, antes del inicio del tratamiento.
    13.Mujeres embarazadas, que estén dando el pecho o que, si son mujeres con capacidad de quedar embarazadas, se considere que no es posible garantizar que van a utilizar métodos anticonceptivos de forma fiable.
    E.5 End points
    E.5.1Primary end point(s)
    The primary efficacy endpoint is the responder rate:
    A patient will be considered a responder if he or she did not receive a blood transfusion from Week 5 through Week 26 (EOT) and did not receive treatment for CAgD beyond what is permitted per protocol. Additionally, the patient’s Hgb level must meet the following criterion:
    •Hgb increase ≥ 1.5 g/dL from baseline (defined as the last Hgb value before administration of the first dose of study drug) at treatment assessment endpoint (defined as mean value from Weeks 23, 25, and 26)
    El criterio de valoración principal de la eficacia es la tasa de pacientes con respuesta al tratamiento. Se considerará que un paciente responde
    al tratamiento si no ha recibido una transfusión sanguínea desde la semana 5 hasta la semana 26 (FDT) y tampoco ha recibido tratamiento
    para la enfermedad por crioaglutininas más allá de lo permitido porprotocolo. Además, el valor de Hb del paciente deberá cumplir el siguiente
    • El valor de Hb es ≥ 15 g/dl desde el valor inicial (definida como el valor de Hb antes de la administración de la primera dosis del fármaco en estudio) al término del período de evaluación del tratamiento (definido como la media de los valores de las semanas 23,
    25 y 26)
    E.5.1.1Timepoint(s) of evaluation of this end point
    Week 26
    Semana 26
    E.5.2Secondary end point(s)
    Secondary Efficacy Endpoints (Part A)
    Mean change from baseline in Hgb at treatment assessment endpoint (mean of values at Week 23, 25, and 26)
    Mean change from baseline in bilirubin (excluding patients with Gilbert’s Syndrome) at treatment assessment endpoint
    Mean change from baseline in QOL, as assessed by the change in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue scale (Appendix E) scores at the treatment assessment endpoint
    Mean change from baseline in lactate dehydrogenase (LDH) at the treatment assessment endpoint
    Incidence of solicited symptomatic anemia at EOT

    Efficacy Endpoints (Part B)
    The following parameters of disease activity will be assessed:
    Bilirubin (total)
    QOL assessments (FACIT-fatigue, EQ-5D-5L, SF-12, and PGIC Scale)
    Transfusion requirementsHaptoglobin
    Criterios secundarios de valoración de eficacia (Parte A)
    •Variación media del valor de Hb respecto al valor basal al término del período de evaluación del tratamiento (media de los valores en las semanas 23, 25 y 26).
    •Variación media del valor de bilirrubina respecto al valor basal (excluyendo a pacientes con síndrome de Gilbert) al término del período de evaluación del tratamiento.
    •Variación media de la puntuación de CdV respecto a la puntuación basal, según la valoración del cambio en las puntuaciones de la escala de Evaluación funcional del tratamiento de enfermedades crónicas (FACIT)-Cansancio al término del período de evaluación del tratamiento.
    •Variación media del valor de lactato deshidrogenasa (LDH) respecto al valor basal al término del período de evaluación del tratamiento.
    •Incidencia de anemia sintomática declarada mediante interrogatorio dirigido en la visita FDT.

    Criterios secundarios de la evakuacion de eficacia (Parte B)
    Se evaluarán los siguientes parámetros de actividad de la enfermedad:
    • Hemoglobina
    • Bilirrubina (total)
    • Evaluaciones de la CdV (FACIT-Cansancio, EQ-5D-5L, SF-12 y escala PGIC)
    •Necesidad de transfusión
    E.5.2.1Timepoint(s) of evaluation of this end point
    Week 23, 25, and 26
    Semanas 23, 25, y 26
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E. trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned4
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA37
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months5
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months5
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 4
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 36
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state2
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 27
    F.4.2.2In the whole clinical trial 40
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Standard of care
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2018-02-06
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2017-12-18
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands